Previous studies have revealed that TEAD4 is usually amplificated and/or overexpressed in multiple cancers including atypical teratoid/rhabdoid tumor, serous ovarian carcinoma, colorectal cancer, lung adenocarcinoma, gastric cancer and OSCC [14, 15, 33, 38–40]. Here, TEAD4 is linked to ovarian serous carcinoma.